PNFP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
BUY now for a near-term rebound + 2026 re-rating setup. Price ($95.03) is sitting just above first support (S1 ~$93.90) after underperformance tied to the Synovus integration narrative, while analyst targets have been repeatedly raised/initiated in January (most Buys/Overweights) implying meaningful upside (roughly mid-teens to ~30%+ depending on target). With no Intellectia proprietary buy signals today, this is a fundamentals/consensus-catalyst-driven buy rather than a pure quant timing entry, but the location near support makes the risk/reward acceptable for an impatient buyer.
Trend is currently bearish but potentially stabilizing near support. Moving averages are stacked bearishly (SMA_200 > SMA_20 > SMA_5), indicating the broader downtrend remains intact. MACD histogram (-0.466) is below zero but negatively contracting, which often signals downside momentum is fading (early bottoming behavior). RSI(6) 41 is neutral-to-soft (not oversold), suggesting there may be room to bounce without being technically stretched. Key levels: Support S1 ~$93.90 then S2 ~$90.68; resistance pivots at ~$99.11 then R1 ~$104.32. A push back above the pivot (99) would be the first clear technical improvement; until then it’s a buy-into-support setup rather than a confirmed uptrend. Pattern-based stats provided imply a modest positive bias (60% chance) with +2.61% next-week expectation.
Analyst momentum: multiple target raises and new Buy initiations in January with “growth at a discount” and 2026 re-rating language post pullback.
Capital return signals: common dividend declared ($0.50/share payable Feb 27,
plus preferred dividends approved—supports confidence in capital base and earnings durability.
Macro/sector tailwinds cited by analysts: steepening curve, improving loan growth, and mid-cap regional catch-up potential in
Synovus merger thesis: several firms frame integration as an idiosyncratic catalyst for earnings enhancement once execution becomes visible.
Technical overhang: still in a bearish MA structure; any break below ~$93.90 risks a quick move toward ~$90.
Merger integration execution risk: multiple analysts note “show me” bias and extended integration timeline; merger-of-equals skepticism can cap near-term multiple expansion.
Hedge fund/insider activity is neutral (no strong incremental sponsorship signal).
Latest provided quarter: 2025/Q3 showed solid growth trends—Revenue $504.189M (+12.41% YoY), Net Income $169.338M (+18.51% YoY), EPS $2.19 (+17.74% YoY). This is a strong profitability and EPS growth profile heading into the integration narrative, consistent with analysts citing a better earnings outlook and capital base.
Recent trend is clearly improving: multiple firms raised price targets after Q4 commentary and several Buy/Outperform/Overweight stances were reiterated or initiated (Piper Sandler Overweight $122; Citi Buy $122; Deutsche Bank initiated Buy $116; Truist Buy $118; TD Cowen Buy $125; Evercore Outperform $115). A minority remains Neutral/Market Perform (UBS Neutral $107; Keefe Bruyette Market Perform $105; DA Davidson Neutral $110), mainly due to near-term integration skepticism. Wall Street ‘pros’ view: attractive re-rating potential + tailwinds in 2026 + earnings/capital confidence. ‘Cons’ view: integration timeline and merger sentiment create a near-term proof-of-execution hurdle. Politician/congress trading: no recent congress trading data available. Intellectia Proprietary Trading Signals: AI Stock Picker—no signal today; SwingMax—no recent signal.
